FDA has recently revised Form 356h: Application to Market a New or Abbreviated New Drug or Biologic for Human Use and Form 1571: Investigational New Drug Application (IND) to align with FDA User Fee requirements as well as make other improvements to data quality and ease of use.
These forms are required to be submitted with NDAs, ANDAs, BLAs and INDs. FDA uses this information in the review process and companies should be aware of these updates and are required to use the most current version of these forms.
Companies need to use the most recent update to Forms 356h and 1571 in their submissions.
View referenced article
Author(s)
Related Insights
July 11, 2025
Foley Viewpoints
Department of Justice Launches Program to Reward Antitrust Whistleblowers with Shares of Criminal Fines
On July 8, 2025, the U.S. Department of Justice, Antitrust Division (“Antitrust Division”) announced a new “Whistleblower Rewards…
July 10, 2025
Foley Viewpoints
One Big Beautiful Bill Act Permanently Increases the Lifetime Estate, Gift and GST Tax Exclusion
On July 4, 2025, President Trump signed into law the One Big Beautiful Bill Act (OBBBA). The OBBBA extended and may permanent many key…
July 10, 2025
Foley Viewpoints
FTC's "Click-to-Cancel" Rule Invalidated
The Federal Appeals Court for the 8th Circuit invalidated the Federal Trade Commission's (FTC) “click-to-cancel” (aka “negative option”)…